Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Comparison of clinical characteristics and outcomes of immune thrombocytopenia in Chinese Han children living at high altitude and sea level.

Created on 23 Oct 2026

Authors

Qingning Yin, Shuqin Shan, Wenya Qian, Guanling Wang, Jing Wang, Baoqin Shi, Binfei Hu, Jianhua Feng, Yifen Shi

Published in

Pediatric hematology and oncology. Pages 1-11. Oct 21, 2026. Epub Oct 21, 2026.

Abstract

Exposure to high altitude can lead to hypobaric hypoxia, which triggers adaptive hematological responses in humans. We examined clinical variation in pediatric immune thrombocytopenia (ITP) across two attitudinally distinct regions and evaluated the influence of altitude on disease outcomes. The study included 156 Chinese Han children with ITP: 68 in the high-altitude group (ALT, Xining City) and 88 in the sea-level group (SEA, Ningbo City). Children in the ALT group were older and presented with higher bleeding grades compared to those in the SEA group. Multivariate logistic regression showed that older age was associated with a significantly greater risk of a prolonged disease course. In contrast, patients who achieved complete response (CR) within 7 days of treatment, as well as those in the ALT group, were less likely to develop a prolonged course. These findings highlight altitude as a potential modifier of pediatric ITP outcomes and warrant further investigation into the underlying mechanisms.

PMID:
42904612
Bibliographic data and abstract were imported from PubMed on 23 Oct 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 11
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement